DC-CTL免疫细胞对4种恶性肿瘤治疗疗效观察

Efficacy of DC-CTL immunological cells on treatment of four malignant tumors

目的初步观察自体DC-CTL免疫细胞回输对4种恶性肿瘤治疗的临床疗效。方法 50例肿瘤患者分为4组,乳腺癌组12例,肺癌组27例,结直肠癌组8例,卵巢癌组3例。分离患者外周血单个核细胞(PBMC),分别诱导培养细胞毒T淋巴细胞(CTL)、树突状细胞(DC),诱导培养细胞达足够数量后回输给患者。分别在治疗前后采用流式细胞术检测患者外周血淋巴细胞CD3+、CD4+、CD8+、CD4+/CD8+和肿瘤标志物的变化,采用主观问卷调查对卡氏行为能力(KPS)进行评分,并对治疗疗效进行评价。结果治疗1个月后,总有效率达82.0%,且未见明显副作用。治疗后1 w,各组外周血CD3、CD4、CD8均显著升高(P<0.05),而CD4+/CD8+无显著变化;各组外周血NK、CIK和KPS评分均显著升高(P<0.05),而CEA、FRP、CA19,CA153均较治疗前明显下降(P<0.05)。结论自体免疫细胞治疗对改善恶性肿瘤患者生活质量,提高患者的免疫功能有明显作用,且安全性好,为恶性肿瘤的治疗提供了一个新的方向。

Objective To preliminarily observe the efficacy of autologous DC-CTL immunological cell infusion on the treatment of four malignant tumors. Methods A total of 50 tumor patients were divided into four groups： the breast cancer group （n=12）, the lung cancer group （n=27）, the colorectal cancer group （n=8） and the ovarian cancer group （n=3）. The peripheral blood mononuclear cells （PBMCs） of the patients were separated for respective induced culture of CTLs and dendritic cells （DCs）. The cells thus cultured were infused to the patients when the number of such ceils was adequate. The changes of CD3＋, CD4＋, CD8＋, CD4＋/CD8＋ and tumor markers in peripheral blood lymphocyte （PBLs） of the patients were detected by flow cytometry before and after the treatment. Subjective questionnaire was conducted to score the KPS and evaluate the efficacy, Results One month after the treatment, the ORR reached 82.0% without any obvious side effects. One week after the treatment, the CD3, CD4 and CD8 in the peripheral blood （PB） in all groups increased significantly（P 〈 0.05）, while CD4＋/CD8＋ showed no obvious change; the scores pf NK, CIK and KPS in the PB in all groups increased greatly（P 〈 0.05）, while CEA, FRP, CA19 and CA153 were much lower than those before the treatment（P 〈 0.05）. Conclusion Autologous immune cell therapy is significantly effective and highly safe on the improvement of the quality of life of tumor patients and their immunologic function, providing a new direction for the treatment of malignant tumors.